Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

F1308

Sigma-Aldrich

Fosinopril sodium

≥98% (HPLC), powder

Synonym(s):

(2S,4S)-4-Cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid, Acecor, Eosinopril, Fosinopril, Monopril, SQ 28555, Secorvas, Staril

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
₩212,338
25 MG
₩614,177

₩212,338

Please contact Customer Service for Availability
New, lower price on this item!
Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
₩212,338
25 MG
₩614,177

About This Item

Empirical Formula (Hill Notation):
C30H45NO7P · Na
CAS Number:
88889-14-9
Molecular Weight:
585.64
MDL number:
MFCD23704184
UNSPSC Code:
12352200
PubChem Substance ID:
329799677
NACRES:
NA.77

₩212,338

Please contact Customer Service for Availability
New, lower price on this item!
Request a Bulk Order

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to off-white

solubility

H2O: >20 mg/mL

originator

Bristol-Myers Squibb

storage temp.

−20°C

SMILES string

O=C([O-])[C@H]1N(C(CP(CCCCC2=CC=CC=C2)(O[C@@H](C(C)C)OC(CC)=O)=O)=O)C[C@H](C3CCCCC3)C1.[Na+]

InChI

1S/C30H46NO7P.Na/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24;/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35);/q;+1/p-1/t25-,26+,30+,39?;/m1./s1

InChI key

TVTJZMHAIQQZTL-TXDYNIFHSA-M

Looking for similar products? Visit Product Comparison Guide

General description

Fosinopril lowers blood pressure and functions as an antihypertensive agent. It is an ester prodrug.[1] Fosinopril is metabolised by the liver and excreted from the body by liver and kidney. It is used to treat heart failure.[2]

Biochem/physiol Actions

Fosinopril is an angiotensin converting enzyme (ACE) inhibitor.
Fosinopril is an angiotensin converting enzyme (ACE) inhibitor. Fosinopril is also known to inhibit the activity of the peptide transporter PEPT2.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Warning

Hazard Statements

H319,H361d

Hazard Classifications

Eye Irrit. 2 - Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000408411
0000408411
0000245709
0000245709
101M4742V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Patrick Rossignol et al.
Hypertension (Dallas, Tex. : 1979), 60(2), 339-346 (2012-07-11)
Optimal blood pressure (BP) targets are still controversial in end-stage renal disease. Recent data have highlighted shortcomings of the usual BP hypothesis in other patient populations and emphasized the importance of visit-to-visit variability of BP in predicting cardiovascular events. The
L Sbârcea et al.
Die Pharmazie, 66(8), 584-589 (2011-09-10)
Fosinopril is one of the most hydrophobic substances among the angiotensin-converting enzyme inhibitors, exhibiting low water solubility and poor bioavailability following oral administration. Inclusion complexes between the drug substance and cyclodextrins (CDs) were obtained in order to improve its solubility.
S Giovannini et al.
The journal of nutrition, health & aging, 14(6), 457-460 (2010-07-10)
The present study evaluates the effects of a 6-month treatment with an ACE-inhibitor (ie, fosinopril) on serum concentrations of total IGF-1 and IGF binding protein (IGFBP)-3 in older adults at high risk for cardiovascular disease. Data are from the Trial
Lakhan Kma et al.
Journal of radiation research, 53(1), 10-17 (2012-02-04)
Our long-term goal is to use angiotensin converting enzyme (ACE) inhibitors to mitigate the increase in lung collagen synthesis that is induced by irradiation to the lung, which could result from accidental exposure or radiological terrorism. Rats (WAG/RijCmcr) were given
Abhishek S Chitnis et al.
Research in social & administrative pharmacy : RSAP, 8(2), 145-156 (2011-04-23)
Heart failure is a major and growing public health problem in United States. There is a substantial evidence about efficacy of angiotensin-converting enzyme inhibitors (ACEIs) in heart failure (HF); however, there is no conclusive evidence on the relative effectiveness of
View All Related Papers

Articles

Angiotensin Receptors

We offer many products related to angiotensin receptors for your research needs.

Discover Bioactive Small Molecules for ADME/Tox

Discover Bioactive Small Molecules for ADME/Tox

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service